Log in

Relevant bibliographies by topics / Drug therapiy / Journal articles

To see the other types of publications on this topic, follow the link: Drug therapiy.

Journal articles on the topic 'Drug therapiy'

Author: Grafiati

Published: 4 June 2021

Last updated: 14 February 2022

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 journal articles for your research on the topic 'Drug therapiy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Petrak, Karel. "The Difference between Targeted Drug Therapies and Targeted-Drug Therapies." Cancer Research and Cellular Therapeutics 2, no. 4 (2018): 01–03. http://dx.doi.org/10.31579/2640-1053/032.

Full text

APA, Harvard, Vancouver, ISO, and other styles

2

Isnenia, Isnenia. "Penggunaan Non-Steroid Antiinflamatory Drug dan Potensi Interaksi Obatnya Pada Pasien Muskuloskeletal." Pharmaceutical Journal of Indonesia 6, no. 1 (2020): 47–55. http://dx.doi.org/10.21776/ub.pji.2020.006.01.8.

Full text

Abstract:

The main therapy on musculoskeletal patients is the use of non-steroidal anti-inflammatory drugs (NSAIDs) either as monotherapy or in combination with drugs of the same class or pain relievers from other groups. The use of more than one drugs have potentially caused drug-drug interactions that can affect to patient. This study was aimed to describe the patient's sociodemographic (sex, ages) and clinical (numbers of drugs, type of drugs and diagnose) characteristics, as well as to find the correlation between potential drug interactions with these variables. This research was a quantitative stu

APA, Harvard, Vancouver, ISO, and other styles

3

R., Akobova, та Ryzhakin S.M. "КОНСЕРВАТИВНАЯ ТЕРАПИЯ ДОБРОКАЧЕСТВЕННОЙ ГИПЕРПЛАЗИИ ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ". Bulletin "Biomedicine and sociology" 4, № 2 (2019): 21–24. http://dx.doi.org/10.26787/nydha-2618-8783-2019-4-2-21-24.

Full text

APA, Harvard, Vancouver, ISO, and other styles

4

Ulfah, Nurbani. "Evaluasi Program Art Therapy Bagi Pasien Dual Diagnosis (NAPZA-Skizofrenia) di Rumah Sakit Ketergantungan Obat (RSKO) Jakarta." EMPATI: Jurnal Ilmu Kesejahteraan Sosial 4, no. 1 (2015): 58–77. http://dx.doi.org/10.15408/empati.v4i1.9767.

Full text

Abstract:

The main problem drug users with psychiatric disorders is the difficulty of communicating the reason they use drugs and express their feelings on the condition of the Counselor or Social Worker (Therapist). The existence of the program of art therapy for patients with drug with psychiatric disorders (dual diagnosis) is part of psychotherapy as an adjunct therapy in the form of art to channel emotions, express their feelings when communicate verbally is difficult, and to express themselves freely in order to improve their condition in the direction better in recovering. In an effort to redress

APA, Harvard, Vancouver, ISO, and other styles

5

Chen, Fengqian, Yunzhen Shi, Jinming Zhang, and Qi Liu. "Nanoparticle-based Drug Delivery Systems for Targeted Epigenetics Cancer Therapy." Current Drug Targets 21, no. 11 (2020): 1084–98. http://dx.doi.org/10.2174/1389450121666200514222900.

Full text

Abstract:

This review summarizes the epigenetic mechanisms of deoxyribonucleic acid (DNA) methylation, histone modifications in cancer and the epigenetic modifications in cancer therapy. Due to their undesired side effects, the use of epigenetic drugs as chemo-drugs in cancer therapies is limited. The drug delivery system opens a door for minimizing these side effects and achieving greater therapeutic benefits. The limitations of current epigenetic therapies in clinical cancer treatment and the advantages of using drug delivery systems for epigenetic agents are also discussed. Combining drug delivery sy

APA, Harvard, Vancouver, ISO, and other styles

6

Leary, Meghan, Sarah Heerboth, Karolina Lapinska, and Sibaji Sarkar. "Sensitization of Drug Resistant Cancer Cells: A Matter of Combination Therapy." Cancers 10, no. 12 (2018): 483. http://dx.doi.org/10.3390/cancers10120483.

Full text

Abstract:

Cancer drug resistance is an enormous problem. It is responsible for most relapses in cancer patients following apparent remission after successful therapy. Understanding cancer relapse requires an understanding of the processes underlying cancer drug resistance. This article discusses the causes of cancer drug resistance, the current combination therapies, and the problems with the combination therapies. The rational design of combination therapy is warranted to improve the efficacy. These processes must be addressed by finding ways to sensitize the drug-resistant cancers cells to chemotherap

APA, Harvard, Vancouver, ISO, and other styles

7

Goyal, Pardeep Kumar, Shalini Arora, Naveen Mittal, Bharti Mahajan, and Sandeep Kaushal. "Prescribing pattern and pharmacoeconomic analysis of antidiabetic drugs." International Journal of Basic & Clinical Pharmacology 8, no. 8 (2019): 1844. http://dx.doi.org/10.18203/2319-2003.ijbcp20193188.

Full text

Abstract:

Background: Diabetes Mellitus is a worldwide growing problem causing threat to patient's health because of its association with various complications and comorbidities. It is a chronic disease requiring lifelong medication which further adds to the economic burden. The objective of this study was to evaluate the prescribing pattern and to do pharmacoeconomic analysis of prescribed antidiabetic drugs.Methods: This observational cross sectional study was conducted for 12 months duration in Outpatient Pharmacy of tertiary care hospital. Prescriptions with antidiabetic drugs were captured and eval

APA, Harvard, Vancouver, ISO, and other styles

8

Nishimura, Kaneyasu, and Kazuyuki Takata. "Combination of Drugs and Cell Transplantation: More Beneficial Stem Cell-Based Regenerative Therapies Targeting Neurological Disorders." International Journal of Molecular Sciences 22, no. 16 (2021): 9047. http://dx.doi.org/10.3390/ijms22169047.

Full text

Abstract:

Cell transplantation therapy using pluripotent/multipotent stem cells has gained attention as a novel therapeutic strategy for treating neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, Huntington’s disease, ischemic stroke, and spinal cord injury. To fully realize the potential of cell transplantation therapy, new therapeutic options that increase cell engraftments must be developed, either through modifications to the grafted cells themselves or through changes in the microenvironment surrounding the grafted region. Together these developments could potentially

APA, Harvard, Vancouver, ISO, and other styles

9

Vandamme, A.-M., K. Van Vaerenbergh, and E. De Clercq. "Anti-Human Immunodeficiency Virus Drug Combination Strategies." Antiviral Chemistry and Chemotherapy 9, no. 3 (1998): 187–203. http://dx.doi.org/10.1177/095632029800900301.

Full text

Abstract:

It is now generally accepted that mono- and bitherapy for human immunodeficiency virus type 1 (HIV-1) infection are only transiently efficient mainly due to virus drug resistance. To obtain a sustained benefit from antiviral therapy, current guidelines recommend at least triple-drug combinations, or the so-called highly active antiretroviral therapy (HAART). In some patients, HAART can be problematic, either because it is difficult to remain compliant or because previous suboptimum therapies have limited the choice of drugs. For compliant drug-naive patients, HAART should be able to offer long

APA, Harvard, Vancouver, ISO, and other styles

10

Su, Yifan. "The Molecular Mechanism and Drug Therapy of Heart Failure." International Journal of Environmental Science and Development 11, no. 9 (2020): 455–59. http://dx.doi.org/10.18178/ijesd.2020.11.9.1290.

Full text

Abstract:

Heart failure (HF) is a complex clinical syndrome that results from left ventricular myocardial dysfunction and contributes to dyspnea, fatigue and fluid retention. It's essential to characterize disease progression and symptoms to optimize therapy selection. Also, understanding the mechanisms of HF to guide therapy selection is of vital importance. This review focuses on the demonstrating mechanisms of HF and points out the possible pathways involved in the process. Drug therapies of HF with different effects on specific targets are analyzed. Finally, we conclude the features of the now going

APA, Harvard, Vancouver, ISO, and other styles

11

Szafir, Deborah, Hervé Lelouët, Jean-Louis Imbs, et al. "Prevention of Drug-Induced Risks." Therapies 58, no. 3 (2003): 225–27. http://dx.doi.org/10.2515/therapie:2003036.

Full text

APA, Harvard, Vancouver, ISO, and other styles

12

Ayar, Koray, Ali Asan, and Tülay Dilara Hattatoğlu. "Evaluation of Hepatitis B Seroprevalence and Hepatitis B Reactivation Frequency in Rheumatology Patients Using Biological Drug Therapy." Klimik Dergisi/Klimik Journal 34, no. 1 (2021): 42–49. http://dx.doi.org/10.36519/kd.2021.08.

Full text

Abstract:

Objective: The presence of hepatitis B virus (HBV) infection in patients using biological drug therapy may cause reactivation. There is insufficient data on the frequency of HBV reactivation, especially after the use of new biological drugs such as tofacitinib, tocilizumab, and secukinumab. This study aims to examine HBV seroprevalence in rheumatology patients using biological drug therapy and investigate the frequency of reactivation in patients with previous HBV infection. Methods: The charts of 275 patients who were followed up in the rheumatology department and used biological drug therapy

APA, Harvard, Vancouver, ISO, and other styles

13

Cho, Heyrim, and Doron Levy. "The impact of competition between cancer cells and healthy cells on optimal drug delivery." Mathematical Modelling of Natural Phenomena 15 (2020): 42. http://dx.doi.org/10.1051/mmnp/2019043.

Full text

Abstract:

Cell competition is recognized to be instrumental to the dynamics and structure of the tumor-host interface in invasive cancers. In mild competition scenarios, the healthy tissue and cancer cells can coexist. When the competition is aggressive, competitive cells, the so called super-competitors, expand by killing other cells. Novel chemotherapy drugs and molecularly targeted drugs are commonly administered as part of cancer therapy. Both types of drugs are susceptible to various mechanisms of drug resistance, obstructing or preventing a successful outcome. In this paper, we develop a cancer gr

APA, Harvard, Vancouver, ISO, and other styles

14

Anggriani, Yusi, Prih Sarnianto, Siti Aisyah, and Jenny Pontoan. "Trend Price Analysis of Drug Before and After the Implementation of E-catalogue at the Hospital." JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice) 9, no. 1 (2019): 1. http://dx.doi.org/10.22146/jmpf.44496.

Full text

Abstract:

In 2013, Ministry of Health, Republic of Indonesia, launched a new change to drug procurement system, namely e-catalogue, to ensure the availability and affordability of medicines. This system replaces the previous auction drug procurement system. The purpose of the change into e-catalogue system is to facilitate the drug procurement in hospitals without the need to conduct complex negotiation with producers, to reduce the occurrence of mark-ups or inflating drug prices, to equalize drug prices, to support BPJS (Badan Penyelenggara Jaminan Sosial) activities, and to prevent difficulties in dru

APA, Harvard, Vancouver, ISO, and other styles

15

Courcier-Duplantier, Soizic, Bruno Falissard, Pierre Fender, et al. "Subjective Outcome Measures of Drug Efficacy." Therapies 58, no. 3 (2003): 267–73. http://dx.doi.org/10.2515/therapie:2003042.

Full text

APA, Harvard, Vancouver, ISO, and other styles

16

Girard, Pascal, Michel Cucherat, David Guez, et al. "Clinical Trial Simulation in Drug Development." Therapies 59, no. 3 (2004): 297–304. http://dx.doi.org/10.2515/therapie:2004057.

Full text

APA, Harvard, Vancouver, ISO, and other styles

17

Wei, Andrew H., and Ing S. Tiong. "Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML." Blood 130, no. 23 (2017): 2469–74. http://dx.doi.org/10.1182/blood-2017-08-784066.

Full text

Abstract:

Abstract In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid leukemia (AML) treatment: targeted therapies for mutant FLT3 and IDH2, a liposomal cytarabine-daunorubicin formulation for therapy-related AML and AML with myelodysplasia-related changes, and resurgence of an antibody-drug conjugate designed to target CD33. Promising results also emerged for the BCL-2 inhibitor venetoclax combined with low-intensity therapy in older patients unfit for intensive chemotherapy. This quintet of new drugs is likely to reshape the therapeutic landscape of AML.

APA, Harvard, Vancouver, ISO, and other styles

18

Antsiferov, M. B., and T. N. Markova. "State-of-the-Art Drug Therapies of Obesity." Doctor.Ru 20, no. 2 (2021): 45–50. http://dx.doi.org/10.31550/1727-2378-2021-20-2-45-50.

Full text

Abstract:

Objective of the Review: To discuss state-of-the-art drug therapies of obesity. Key Points. Obesity is a socially significant healthcare problem, because it is associated with major conditions limiting life expectancy. The problem of obesity dates back to the period of Hippocrates; however, efficient drugs appeared as late as in the ХХI century. The article is a review of the state-of-the-art drug therapies for body weight reduction approved in the Russian Federation. It describes the efficiency and side effects and a case of obesity management with Liraglutide 3mg. Conclusion. Obese and overw

APA, Harvard, Vancouver, ISO, and other styles

19

Gupta, P. D. "Reducing drug resistance should be the aim of therapies." Clinical Research and Clinical Trials 3, no. 4 (2021): 01–05. http://dx.doi.org/10.31579/2693-4779/028.

Full text

Abstract:

Over the period, due to evolutionary constrains, gene mutations, changes in micro- and mega- environment gave a tool to bacteria to adopt for survival in the hostile environment. When they are exposed with broad spectrum antibiotics, they have adopted to live and become resistant to antibiotics. In this review many preventive and curative strategies has been described to avoid antibiotics. These lines of treatments would not give chances to microbes to become drug resistant. “Prevention is better than cure” adopting this strategy we have described immunochemicals and many herbal medicines whic

APA, Harvard, Vancouver, ISO, and other styles

20

Bandagi, Dr Rupali. "Therapeutic Drug Monitoring of Carbamazepine and Phenytoin: Monotherapy versus Combination Therapy." Journal of Medical Science And clinical Research 05, no. 05 (2017): 22674–80. http://dx.doi.org/10.18535/jmscr/v5i5.230.

Full text

APA, Harvard, Vancouver, ISO, and other styles

21

Aouinti, Imen, Rim Charfi, Sameh Trabelsi, et al. "Vancomycin Therapeutic Drug Monitoring in Cerebrospinal Fluid." Therapies 69, no. 6 (2014): 529–30. http://dx.doi.org/10.2515/therapie/2014204.

Full text

APA, Harvard, Vancouver, ISO, and other styles

22

Atkinson, Jeffrey. "A Postgraduate Course in Preclinical Drug Evaluation." Therapies 59, no. 1 (2004): 61–62. http://dx.doi.org/10.2515/therapie:2004013.

Full text

APA, Harvard, Vancouver, ISO, and other styles

23

Zhang, Hongbo, Wenguo Cui, Xiangmeng Qu, et al. "Photothermal-responsive nanosized hybrid polymersome as versatile therapeutics codelivery nanovehicle for effective tumor suppression." Proceedings of the National Academy of Sciences 116, no. 16 (2019): 7744–49. http://dx.doi.org/10.1073/pnas.1817251116.

Full text

Abstract:

Effective cancer therapies often demand delivery of combinations of drugs to inhibit multidrug resistance through synergism, and the development of multifunctional nanovehicles with enhanced drug loading and delivery efficiency for combination therapy is currently a major challenge in nanotechnology. However, such combinations are more challenging to administer than single drugs and can require multipronged approaches to delivery. In addition to being stable and biodegradable, vehicles for such therapies must be compatible with both hydrophobic and hydrophilic drugs, and release drugs at susta

APA, Harvard, Vancouver, ISO, and other styles

24

Jurkowska, Karolina, and Anna Długosz. "Research on new drugs in the therapy of bladder cancer (BC)." Postępy Higieny i Medycyny Doświadczalnej 72 (May 17, 2018): 442–48. http://dx.doi.org/10.5604/01.3001.0012.0539.

Full text

Abstract:

New, more effective and safer therapies in bladder cancer are being developed. Most attention is focused on monoclonal antibody therapies, targeted therapies and immunotherapy. Numerous pre-clinical and clinical studies on the use of the new drugs in bladder cancer are currently in progress. The great hope is associated with monoclonal antibodies, which are immune checkpoint inhibitors. Last year, two drugs from this group (Atezolizumab and Nivolumab) have been approved by Food and Drug Administration (FDA) for the treatment of muscle invasive bladder cancer (MIBC). Other monoclonal antibodies

APA, Harvard, Vancouver, ISO, and other styles

25

Zhu, Chuan-cong, Si-yu Fu, Yu-xin Chen, et al. "Advances in Drug Therapy for Alzheimer’s Disease." Current Medical Science 40, no. 6 (2020): 999–1008. http://dx.doi.org/10.1007/s11596-020-2281-2.

Full text

Abstract:

SummaryAlzheimer’s disease (AD) is a chronic neurodegenerative disease that mainly causes dementia. It is a serious threat to the health of the global elderly population. Considerable money and effort has been invested in the development of drug therapy for AD worldwide. Many drug therapies are currently under development or in clinical trials, based on two known mechanisms of AD, namely, Aβ toxicity and the abnormal Tau hyperphosphorylation. Numerous drugs are also being developed for other AD associated mechanisms such as neuroinflammation, neurotransmitter imbalance, oxidative damage and mi

APA, Harvard, Vancouver, ISO, and other styles

26

Chawla, Anita, Filip Janku, Jennifer J. Wheler, et al. "Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study." JCO Precision Oncology, no. 2 (November 2018): 1–11. http://dx.doi.org/10.1200/po.18.00074.

Full text

Abstract:

Purpose Comprehensive genomic profiling (CGP) detects several classes of genomic alterations across numerous genes simultaneously and can match more patients with genomically targeted therapies than conventional molecular profiling. The current study estimated the costs of anticancer drugs and overall survival (OS) for patients who were treated with matched and unmatched therapy. Methods Costs were estimated for patients with complete data (188 of 500 patients) from a prospective, nonrandomized study of patients with diverse refractory cancers who underwent CGP and were treated with matched or

APA, Harvard, Vancouver, ISO, and other styles

27

Hu, Jason, Armen G. Aprikian, Marie Vanhuyse, and Alice Dragomir. "Cancer Drug Use in the Last Month of Life in Men With Castration-Resistant Prostate Cancer." Journal of Oncology Practice 15, no. 6 (2019): e510-e519. http://dx.doi.org/10.1200/jop.18.00626.

Full text

Abstract:

PURPOSE: Several new drug therapies have been approved in CRPC in the past decade. However, little is known about their potential overuse at the end of life. Cancer therapy use at the end of life has been considered an indicator of overtreatment. The study objective was to describe CRPC drug use in the last month of life of CRPC patients in Quebec. PATIENTS AND METHODS: Using administrative databases from the province of Quebec in Canada, we identified patients who received medical or surgical castration treatment, received one or more CRPC drugs (chemotherapy, abiraterone, or bone-targeted th

APA, Harvard, Vancouver, ISO, and other styles

28

Sessa, Ben, and Matthew W. Johnson. "Can psychedelic compounds play a part in drug dependence therapy?" British Journal of Psychiatry 206, no. 1 (2015): 1–3. http://dx.doi.org/10.1192/bjp.bp.114.148031.

Full text

Abstract:

SummaryAfter a 40-year hiatus there is now a revisiting of psychedelic drug therapy throughout psychiatry, with studies examining the drugs psilocybin, ketamine, ibogaine and ayahuasca in the treatment of drug dependence. Limitations to these therapies are both clinical and legal, but the possibility of improving outcomes for patients with substance dependency imposes an obligation to research this area.

APA, Harvard, Vancouver, ISO, and other styles

29

Chaabane, Amel, Nadia Ben Fredj, Zohra Chadly, Naceur A. Boughattas, and Karim Aouam. "Fixed Drug Eruption: a Selective Reaction to Amoxicillin." Therapies 68, no. 3 (2013): 183–85. http://dx.doi.org/10.2515/therapie/2013027.

Full text

APA, Harvard, Vancouver, ISO, and other styles

30

Burlingame, Mark B., and Jeffrey C. Delafuente. "Treatment of Systemic Lupus Erythematosus." Drug Intelligence & Clinical Pharmacy 22, no. 4 (1988): 283–89. http://dx.doi.org/10.1177/106002808802200401.

Full text

Abstract:

Systemic lupus erythematosus (SLE) is an autoimmune disease with clinical manifestations involving a multitude of tissue sites. This article describes the pathophysiology, etiology, clinical manifestations, and therapy of SLE, and focuses mainly on drugs used in SLE treatment. The reader will be able to identify which pharmacologic agents are used in SLE and list the drugs that are useful for specific clinical manifestations. The reader will also be able to describe the common adverse drug reactions seen from SLE treatment and the potential risks involved with these therapies. Information on e

APA, Harvard, Vancouver, ISO, and other styles

31

Gilad, Yosi, Gary Gellerman, David M. Lonard, and Bert W. O’Malley. "Drug Combination in Cancer Treatment—From Cocktails to Conjugated Combinations." Cancers 13, no. 4 (2021): 669. http://dx.doi.org/10.3390/cancers13040669.

Full text

Abstract:

It is well recognized today that anticancer drugs often are most effective when used in combination. However, the establishment of chemotherapy as key modality in clinical oncology began with sporadic discoveries of chemicals that showed antiproliferative properties and which as a first attempt were used as single agents. In this review we describe the development of chemotherapy from its origins as a single drug treatment with cytotoxic agents to polydrug therapy that includes targeted drugs. We discuss the limitations of the first chemotherapeutic drugs as a motivation for the establishment

APA, Harvard, Vancouver, ISO, and other styles

32

ISI-SENAI-CIMATEC Group and Development and Innovation Laboratory of Butantan Institute. "Therapies Against COVID-19: a Running to a Treatment." JOURNAL OF BIOENGINEERING AND TECHNOLOGY APPLIED TO HEALTH 3, no. 2 (2020): 184–248. http://dx.doi.org/10.34178/jbth.v3i2.125.

Full text

Abstract:

There is no specific drug or therapy against COVID-19. Since the beginning of the pandemic, scientists are running to discover a drug or therapy that can treat the disease. What we found until now are a combined drug and therapies that can mitigate the effects of the disease in the human body and how to manage the patient better. In this article, we tried to join the new discoveries and presented the drugs and therapies and their mechanisms to combat the SARS-CoV-2. We showed the immunomodulators, parasiticides, antiviral drugs (focused on Remdesivir), antimalarial drugs, anti-cytokine drugs f

APA, Harvard, Vancouver, ISO, and other styles

33

Grinnan, Daniel, Cory Trankle, Adam Andruska, Bruce Bloom, and Edda Spiekerkoetter. "Drug repositioning in pulmonary arterial hypertension: challenges and opportunities." Pulmonary Circulation 9, no. 1 (2019): 204589401983222. http://dx.doi.org/10.1177/2045894019832226.

Full text

Abstract:

Despite many advances in medical therapy for pulmonary arterial hypertension (PAH) over the past 20 years, long-term survival is still poor. Novel therapies which target the underlying pathology of PAH and which could be added to current vasodilatory therapies to halt disease progression and potentially reverse pulmonary vascular remodeling are highly sought after. Given the high attrition rates, substantial costs, and slow pace of new drug development, repositioning of “old” drugs is increasingly becoming an attractive path to identify novel treatment options, especially for a rare disease su

APA, Harvard, Vancouver, ISO, and other styles

34

MBBS MD, Dr Asmita Jain. "Metformin in Cancer Prevention and Therapy: New Application of an Old Drug." Journal of Medical Science And clinical Research 05, no. 04 (2017): 20333–37. http://dx.doi.org/10.18535/jmscr/v5i4.97.

Full text

APA, Harvard, Vancouver, ISO, and other styles

35

Debruyne, Danièle, Marie-Anne Courné, Reynald Le Boisselier, et al. "La méphédrone : une designer drug d’usage récent en France." Therapies 65, no. 6 (2010): 519–24. http://dx.doi.org/10.2515/therapie/2010077.

Full text

APA, Harvard, Vancouver, ISO, and other styles

36

Bejan-Angoulvant, Theodora, Jean-Philippe Baguet, Sylvie Erpeldinger, et al. "The IDEAL Study : Towards Personalized Drug Treatment of Hypertension." Therapies 67, no. 3 (2012): 195–204. http://dx.doi.org/10.2515/therapie/2012031.

Full text

APA, Harvard, Vancouver, ISO, and other styles

37

CDM, Naidu, Vardhan A, Bankar MA, Sharma S, Raghuvanshi VS, and Reddy S. "A Drug Utilisation Study of Antihyperglycaemic Agents in a Rural Tertiary Care Hospital." International Journal of Medical and Dental Sciences 6, no. 1 (2017): 1357. http://dx.doi.org/10.18311/ijmds/2017/18789.

Full text

Abstract:

<p><strong>Background</strong>: Diabetes mellitus is an emerging non communicable, life style disease. The aim was to evaluate the drug utilization pattern of anti-diabetic drugs in diabetic outpatients and monitor the adverse drug reactions (ADRs) associated with anti-diabetic therapy.</p><p><strong>Materials and</strong> <strong>methods</strong>: A prospective observational study was carried out in adult diabetic patients from the Department of General Medicine of a rural tertiary care hospital in October 2013- December 2014 after obtaini

APA, Harvard, Vancouver, ISO, and other styles

38

Buckel, P. "Recombinant Protein Drugs.( Milestones in Drug Therapy)." Molecules 6, no. 12 (2001): 1063. http://dx.doi.org/10.3390/61201063.

Full text

APA, Harvard, Vancouver, ISO, and other styles

39

Sureda, Manuel, Joseba Rebollo, Ramón González-Manzano, et al. "Transcriptome (RNA next generation sequencing) for personalizing of cancer treatment: A correlation with previous clinical resistance." Journal of Clinical Oncology 39, no. 15_suppl (2021): e15046-e15046. http://dx.doi.org/10.1200/jco.2021.39.15_suppl.e15046.

Full text

Abstract:

e15046 Background: RNA Next Generation Sequencing (transcriptome) is a potential useful tool to predict chemoresistance to available anticancer drug therapy. A correlation between previous clinical resistance and drug resistance profiling according to RNA NGS results has been studied. Methods: Since March 2018, whole transcriptome RNA NGS has been performed using Ion-Torrent GeneStudio S5 System in fresh-frozen biopsies obtained from tru-cut or surgical excision procedures from patients with resistant metastatic cancer. We have selected patients with clinically unequivocal drug resistance to p

APA, Harvard, Vancouver, ISO, and other styles

40

Chen, Dazhong, Fangyuan Xie, Duxin Sun, Chuan Yin, Jie Gao, and Yanqiang Zhong. "Nanomedicine-Mediated Combination Drug Therapy in Tumor." Open Pharmaceutical Sciences Journal 4, no. 1 (2017): 1–10. http://dx.doi.org/10.2174/1874844901704010001.

Full text

Abstract:

Background:Combined chemotherapy has gradually become one of the conventional methods of cancer treatment due to the limitation of monotherapy. However, combined chemotherapy has several drawbacks that may lead to treatment failure because drug synergy cannot be guaranteed, achievement of the optimal synergistic drug ratio is difficult, and drug uptake into the tumor is inconsistent. Nanomedicine can be a safe and effective form of drug delivery, which may address the problems associated with combination chemotherapy.Objective:This review summarizes the recent research in this area, including

APA, Harvard, Vancouver, ISO, and other styles

41

Mehta, Sandhya, Jinlin Song, Melissa Pavilack, et al. "Utilization of anti-HER2 regimens among HER2-positive metastatic breast cancer patients." Journal of Clinical Oncology 38, no. 29_suppl (2020): 282. http://dx.doi.org/10.1200/jco.2020.38.29_suppl.282.

Full text

Abstract:

282 Background: HER2-positive (+) metastatic breast cancer (mBC) has a poor prognosis and many patients require multiple lines of HER2 targeted regimens. This study aims to examine the treatment sequencing of anti-HER2 regimens for HER2+ mBC among Medicare beneficiaries. Methods: A retrospective study was conducted using linked 1999-2016 Surveillance, Epidemiology, and End Results (SEER) cancer registries and Medicare claims. Adults patients who had mBC diagnosis, HER2+ status documented in SEER or claims of ≥1 anti-HER2 drug, continuous enrollment in Medicare from the date of mBC diagnosis un

APA, Harvard, Vancouver, ISO, and other styles

42

Pemovska, Tea, Mika Kontro, Bhagwan Yadav, et al. "Identification Of AML Subtype-Selective Drugs By Functional Ex Vivo Drug Sensitivity and Resistance Testing and Genomic Profiling." Blood 122, no. 21 (2013): 482. http://dx.doi.org/10.1182/blood.v122.21.482.482.

Full text

Abstract:

Introduction Adult acute myeloid leukemia (AML) exemplifies the challenges of modern cancer drug discovery and development in that molecularly targeted therapies are yet to be translated into clinical use. No effective second-line therapy exists once standard chemotherapy fails. While many genetic events have been linked with the onset and progression of AML, the fundamental disease mechanisms remain poorly understood. There is significant genomic and molecular heterogeneity among patients. Several targeted therapies have been investigated for improved second-line AML therapy but none has been

APA, Harvard, Vancouver, ISO, and other styles

43

Charfi, Rim, Sihem El Aïdli, Ahmed Zaïem, et al. "Serious Adverse Drug Reactions in Older Adults Notified to Pharmacovigilance." Therapies 67, no. 5 (2012): 465–70. http://dx.doi.org/10.2515/therapie/2012060.

Full text

APA, Harvard, Vancouver, ISO, and other styles

44

Lapeyre-Mestre, Maryse, and Mathilde Dupui. "Drug Abuse Monitoring: Which Pharmacoepidemiological Resources at the European Level?" Therapies 70, no. 2 (2015): 157–65. http://dx.doi.org/10.2515/therapie/2015010.

Full text

APA, Harvard, Vancouver, ISO, and other styles

45

Laveille, Christian, and Roeline Jochemsen. "Pharmacokinetics-Pharmacodynamics During Drug Development – An Example from Servier: Ivabradine." Therapies 59, no. 2 (2004): 173–77. http://dx.doi.org/10.2515/therapie:2004033.

Full text

APA, Harvard, Vancouver, ISO, and other styles

46

Hossein-Ardeschir, Ghofrani, Ralph Schermuly, Norbert Weissmann, et al. "Drug Interactions in Pulmonary Arterial Hypertension and Their Implications." European Cardiology Review 5, no. 1 (2009): 46. http://dx.doi.org/10.15420/ecr.2009.5.1.46.

Full text

Abstract:

Medical intervention is necessary in the treatment of pulmonary arterial hypertension (PAH) in order to prevent chronic disease progression and clinical deterioration. Recent years have seen the development of new disease-specific drugs, such as endothelin receptor antagonists (ERAs). However, there remains the potential for drug–drug interactions (DDIs), which can adversely affect drug metabolism and therefore treatment efficacy, an especially significant factor to consider in light of the increasing use of combination therapy in PAH and the ageing patient population who may also suffer age-r

APA, Harvard, Vancouver, ISO, and other styles

47

Becker, W. J. "Evidence Based Migraine Prophylactic Drug Therapy." Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 26, no. 3 (1999): 27–32. http://dx.doi.org/10.1017/s0317167100000160.

Full text

Abstract:

Prophylactic drug therapy is a major component of overall migraine management. However, because we do not know how currently used prophylactic drugs exert their beneficial effects in migraine, their use is based primarily on clinical trials. In general, prophylactic drugs are indicated when patients have three or more attacks a month and symptomatic medication use alone is not satisfactory. The choice of drug must be individualized, and is influenced by contraindications, potential side effects, the need to treat associated symptoms like tension-type headache and insomnia, and drug cost. Wheth

APA, Harvard, Vancouver, ISO, and other styles

48

Mertz, Gregory J. "Book Review: AIDS Therapy." Drug Resistance Updates 3, no. 3 (2000): 191. http://dx.doi.org/10.1054/drup.2000.0134.

Full text

APA, Harvard, Vancouver, ISO, and other styles

49

Wtorek, Karol, Angelika Długosz, and Anna Janecka. "Drug resistance in topoisomerase-targeting therapy." Postępy Higieny i Medycyny Doświadczalnej 72 (December 21, 2018): 1073–83. http://dx.doi.org/10.5604/01.3001.0012.8131.

Full text

Abstract:

Drug resistance is a well-known phenomenon that occurs when initially responsive to chemotherapy cancer cells become tolerant and elude further effectiveness of anticancer drugs. Based on their mechanism of action, anticancer drugs can be divided into cytotoxic-based agents and target-based agents. An important role among the therapeutics of the second group is played by drugs targeting topoisomerases, nuclear enzymes critical to DNA function and cell survival. These enzymes are cellular targets of several groups of anticancer agents which generate DNA damage in rapidly proliferating cancer ce

APA, Harvard, Vancouver, ISO, and other styles

50

Levy, Richard. "Costs and Benefits of Pharmaceuticals: The Value Equation for Older Americans." Care Management Journals 3, no. 3 (2002): 135–43. http://dx.doi.org/10.1891/cmaj.3.3.135.57447.

Full text

Abstract:

Recent increases in drug expenditures are primarily due to the availability of more and better therapy rather than price inflation. Investment in new drugs generates savings throughout the health care system. Increased use of drugs, especially newer agents, has also resulted in increased longevity and reduced disability. Benefits from new pharmaceuticals far outweigh their costs for many key diseases of the elderly. Even incremental improvements in drug therapies contribute substantially to improved care. Chronic illness, disability, and an aging population will drive future health care spendi

APA, Harvard, Vancouver, ISO, and other styles

We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!